In a double-blind randomized comparative study, 75 patients with dermatomycoses (one cutaneous candidosis and 74 dermatophyte infections) were treated with amorolfine cream 0.125% (group A, 25 patients), 0.25% (group B, 25 patients) or 0.5% (group C, 25 patients). Treatment, consisting of a once daily application, was continued for 1 week after clinical cure, the maximum duration of treatment was limited to 6 weeks. Assessment of the results was based on both clinical and mycological parameters. At the end of the treatment clinical cure rates ranged from 76% to 84%, and mykological cure ranged from 64% to 76%. There were two patients in each group (8%) who did not respond to the treatment, and eight patients had to withdraw due to side-effects. At the assessment 2 months post-therapy 20 patients (80%) in group A, 17 (68%) in group B and 18 (72%) in group C were cured. There were six relapses: 3 (12%) in group B and 3 (12%) in group C. There was no significant difference between the three groups in terms of clinical and mycological response, duration of treatment or tolerance.